Amandine Breton

Amandine Breton is Director of MSAT at Orchard Therapeutics. The MSAT group is composed of cell process and lentiviral vector MSAT and Analytical Sciences. She joined Orchard Therapeutics in 2019 where she oversees and manages cell and gene therapy drug product manufacture from pivotal clinical trials to commercial manufacture, including authoring of regulatory filings (IND, IMPD, MAA, BLA). In addition to her MSAT responsibility, she has lead Strimvelis® CMC lifecycle management team from 2020 to mid-2022. Amandine has a BSc and MSc from the University of Versailles St-Quentin (UVSQ) and a PhD in Cellular Biology from UVSQ. She did 3 post-docs at the Roslin Institute, Queen’s Mary University and King’ College London working in induced pluripotent stem cells biology, hematopoietic cells and globin gene activation in the context of beta-thalassaemia and sickle cell disease. She then chose to join the CGT field and held two consecutive positions in GMP manufacture at Guy’s and St Thomas GMP unit and CRUK GMP manufacture where she worked on autologous and allogenic cell therapies in phase I/II clinical trial building her expertise in technology transfer, process development and GMP manufacturing processes